SYMBION’S strategy to revive its
Faulding brand has paid off, with
the company reporting strong sales
growth across Faulding’s five new
products.
Of particular note is Faulding’s
Probiotic 30s which is achieving an
average of 8% month-on-month
sales growth since its launch last year.
In a bid to further push sales
growth and build brand awareness
the company also recently launched
a TV advertising campaign, as well
as a new website in support of
Faulding Probiotic 90 which has
been added after feedback from
pharmacists at the APP conference..
Symbion has also extended its TV
campaign and is sponsoring Ch 7’s
Sunrise program for a six week slot.
“It’s certainly an exciting time for
the brand. As well as the new
advertising campaign we have a
number of new products in the
pipeline which will be launched in
2011,” said Melanie Bosanko,
Product Manager for Symbion
Consumer ProductsThe above article was sent to subscribers in Pharmacy Daily's issue from 27 Jun 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jun 11
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.